Physician profile
Sapna Singh
NPI 1831116706
$1,029.57
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $33.82 · 2021: $13.62 · 2022: $217 · 2023: $184 · 2024: $130 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $145.25 | 2019-2022 | |
| Corium, LLC | $143.33 | 2022-2024 | Azstarys |
| Ars Pharmaceuticals Operations, INC. | $139.60 | 2025 | Neffy |
| Pfizer INC. | $130.62 | 2019-2025 | |
| Tris Pharma INC | $91.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.93 | 2022-2023 | Elaprase, Vpriv |
| Cranial Technologies, INC | $59.67 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $53.67 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $45.65 | 2023-2024 | Crysvita, Crysvita |
| Merck Sharp & Dohme LLC | $35.03 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $26.07 | 2025 | |
| Seqirus USA INC | $23.30 | 2025 | Flucelvax |
| Astrazeneca Pharmaceuticals LP | $19.24 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $18.52 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $15.44 | 2023 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.